Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
79.8M
-
Number of holders
-
90
-
Total 13F shares, excl. options
-
17.6M
-
Shares change
-
+746K
-
Total reported value, excl. options
-
$64.3M
-
Value change
-
+$3.09M
-
Put/Call ratio
-
0.12
-
Number of buys
-
43
-
Number of sells
-
-24
-
Price
-
$3.65
Significant Holders of Niagen Bioscience, Inc. - Common Stock (NAGE) as of Q3 2024
101 filings reported holding NAGE - Niagen Bioscience, Inc. - Common Stock as of Q3 2024.
Niagen Bioscience, Inc. - Common Stock (NAGE) has 90 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 17.6M shares
of 79.8M outstanding shares and own 22.09% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (3.43M shares), BlackRock, Inc. (3.4M shares), Tieton Capital Management, LLC (2.96M shares), ICONIQ Capital, LLC (1.3M shares), GEODE CAPITAL MANAGEMENT, LLC (1.15M shares), STATE STREET CORP (618K shares), RENAISSANCE TECHNOLOGIES LLC (424K shares), NORTHERN TRUST CORP (378K shares), JPMORGAN CHASE & CO (332K shares), and Royal Bank of Canada (201K shares).
This table shows the top 90 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.